Mereo BioPharma, a multi-asset biopharmaceutical company focused on the acquisition, development and commercialisation of innovative therapeutics that aim to improve outcomes for patients with rare and specialty diseases, announced the appointment of Wills Hughes-Wilson as Head of Patient Access and Commercial Planning.
In her role, Hughes-Wilson will be responsible for leading and optimising Mereo’s patient access and commercialisation strategies, initially in a part-time role as the company builds out its rare disease commercial infrastructure.
Dr Denise Scots-Knight, CEO of Mereo BioPharma, said: “Hughes-Wilson brings in-depth market access and product launch expertise as well as a proven ability to develop and lead commercial planning efforts globally."
"With extensive experience in the rare and orphan disease areas, Hughes-Wilson will be instrumental as we advance our portfolio of rare product candidates through late-stage clinical development and towards commercialisation. We are very pleased to welcome her and believe she will be a strong complement to our existing leadership team at Mereo.”
Most recently, Hughes-Wilson served on the Executive Leadership Team as Chief Patient Access Officer and Senior VP Access and External Affairs at Swedish Orphan Biovitrum (Sobi), an international specialty healthcare company dedicated to rare diseases.
In her role, Hughes-Wilson was responsible for Sobi’s go-to-market commercialisation approach and led the pricing, reimbursement and access teams for Sobi’s rare disease product portfolio.
Prior to joining Sobi, Hughes-Wilson served as VP of Health and Market Access Policy at Genzyme Corporation (now part of Sanofi).
“I am thrilled to join Mereo’s leadership team at such a pivotal time for the Company,” said Hughes-Wilson.
“Mereo’s robust portfolio of product candidates, including BPS-804 for the treatment of osteogenesis imperfecta and AZD-9668 for the treatment of severe alpha-1 antitrypsin deficiency, has the potential to address significant unmet medical needs in rare diseases."
"I look forward to applying my experience to help the Company continue its journey to develop these therapies and, if approved, make them commercially available to patients and healthcare systems in a timely and sustainable manner.”
